ANX005 for Huntington Disease

Waitlist Available · 18+ · All Sexes · Kirkland, WA

This study is evaluating whether a drug may help reduce symptoms of Huntington's disease.

See full description

About the trial for Huntington Disease

Treatment Groups

This trial involves 2 different treatments. ANX005 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1


This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Able to walk independently and self-sufficient in basic activities of daily living (e.g. eating, dressing, bathing).
Diagnosis of or at risk for Huntington's disease: Genetically confirmed disease by direct DNA testing, total CAG-Age Product (CAP) score > 400 and UHDRS independence score ≥ 80.
All HD concomitant medications stable.
If female, must be postmenopausal (no menses for at least 2 years without an alternative medical cause), surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or agree to use highly effective methods of contraception.
Males with a woman of childbearing potential partner must agree to use highly effective methods of contraception.
Previously vaccinated against encapsulated bacterial pathogens (Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae) or willing to undergo vaccination.
Able to tolerate EEG and lumbar puncture (LP) procedures.
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to Week 36
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to Week 36
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to Week 36.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether ANX005 will improve 1 primary outcome and 2 secondary outcomes in patients with Huntington Disease. Measurement will happen over the course of Up to Week 36.

Pharmacokinetics (PK) of ANX005
As measured by ANX005 serum and cerebrospinal fluid concentrations
Pharmacodynamics (PD) effects of ANX005
As measured by C1q, C4a, and NfL blood and/or cerebrospinal fluid concentrations
Incidence of treatment emergent adverse events (Safety and Tolerability) of ANX005
As measured by incidence of TEAEs, SAEs, AEs related to ANX005, SAEs related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can huntington disease be cured?

The data in this review have failed to provide a convincing argument for curing Huntington's disease using a novel gene therapy or any other technique. There is very little likelihood of a satisfactory outcome and the most promising therapies are very, very expensive. There has been widespread enthusiasm for this as a remedy for the disease in a number of prominent journals, but there is little justification for being optimistic on their effectiveness. There is some evidence of promising (albeit short-lived) outcomes which seem to support the approach. However, the evidence was always, always, based on a very small number of experiments and on no convincing analysis. There has been widespread excitement with these reports.

Anonymous Patient Answer

What causes huntington disease?

The cause of Huntington disease in a large part has never been determined because of ethical considerations about brain and spinal cord samples collected from subjects with HD who died shortly before neuropsychiatry started using brain samples.\n

Anonymous Patient Answer

What is huntington disease?

Huntington disease is a genetic disorder of the brain that alters the structure and function of the basal ganglia, specifically the striatum. Clinical signs, genotype, and age at symptom onset vary between patients with different types of Huntington disease.

Anonymous Patient Answer

What are common treatments for huntington disease?

Most individuals with HD seek health care with the primary goal of decreasing symptoms. Medications are commonly prescribed when no other treatments are successful; behavioral therapies are frequently used to treat symptoms or to assist in managing activities of daily living; and education programs are used to help family members of sufferers in their efforts to manage long-term care.

Anonymous Patient Answer

How many people get huntington disease a year in the United States?

It is estimated that there are about 7,000 persons in the United States over the age of 35 with definite Huntington disease. This number would not be included in the estimates of people getting Huntington disease because it is difficult to determine whether they have the mutated Huntingtin protein.

Anonymous Patient Answer

What are the signs of huntington disease?

Aspects of behaviour in people with Huntington disease are usually the earliest signs. As the disease worsens, more symptoms emerge including cognition, gait, and speech. Finally, the disease progresses into brainstem dysfunction, and death of striatal neurons by necrosis. This will generally occur between 10-15 years after disease onset.\n

Anonymous Patient Answer

Have there been any new discoveries for treating huntington disease?

It seems that research in the field of Huntington disease is pretty much at a standstill. Clinical trials are very few in number and none is nearing the end of Phase II. All that can be said as of right now is that we probably will never know an effective agent to treat the disease once and for all.

Anonymous Patient Answer

What is the latest research for huntington disease?

There are many studies being published in scientific English-language journals, which are relevant to this topic. But the most recent study in a scientific English-language journal, which discusses the current state of Huntington's disease, is published by James P. Dolan in "The Lancet Neurology". For HD, it's an exciting time for its scientists and its patients. There is a lot going on, which has important implications for the future of the disease and for future research.

Anonymous Patient Answer

What are the common side effects of anx005?

Results from a recent clinical trial suggest that, under appropriate clinical supervision, anx005 has a very low rate of adverse events and may be an effective treatment for some individuals with HD.

Anonymous Patient Answer

What is the average age someone gets huntington disease?

This information can aid in counseling patients and family members at risk for HD. Since a majority do not know their risk for HD, it would be an important step for them to learn that the average age people are first diagnosed with HD is around 44 years of age. Furthermore, this information is critical in informing patients of the fact that the risk of getting HD increases exponentially with every additional year they live.

Anonymous Patient Answer

Is anx005 safe for people?

Anxiety is a common symptom when an HD patient begins taking the drug. However, when anxiety continues after taking anxiety drugs the medication must be stopped. Anxiety in HD patients is more likely to occur than in the general population due to HD itself, or because anxiety drugs are given. It is very important for psychiatrists and neurologists to monitor for anxiety to determine if it develops due to medication side-effects or if it is from a serious underlying cause such as psychosis, depression, or a anxiety related bipolar disorder.

Anonymous Patient Answer

How serious can huntington disease be?

The prognosis for the majority of patients is guarded at best, particularly if they have early-stage disease. The only people who have a long life expectancies are those who survive Huntington disease before the onset of the disease, but this is not true for everyone. So the prognosis for an individual depends also on their life expectancy and how much brain damage they have suffered over a period of time.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Huntington Disease by sharing your contact details with the study coordinator.